Today's Veterinary Practice

TVP_JUL-AUG2018

Today's Veterinary Practice provides comprehensive information to keep every small animal practitioner up to date on companion animal medicine and surgery as well as practice building and management.

Issue link: https://todaysveterinarypractice.epubxp.com/i/997103

Contents of this Issue

Navigation

Page 36 of 87

CONTINUING EDUCATION todaysveterinarypractice.com JULY/AUGUST 2018 35 11400 Tomahawk Creek Parkway, Suite 340, Leawood, KS 66211 1-844-ARATANA ©2018 Aratana Therapeutics, Inc. ENTYCE is a registered trademark of Aratana Therapeutics, Inc IMPORTANT SAFETY INFORMATION: ENTYCE ® (capromorelin oral solution) is for use in dogs only. Do not use in breeding, pregnant or lactating dogs. Use with caution in dogs with hepatic dysfunction or renal insufficiency. Adverse reactions in dogs may include diarrhea, vomiting, polydipsia, and hypersalivation. Should not be used in dogs that have a hypersensitivity to capromorelin. See page 12 for product information summary. Please see the full Prescribing Information at entyce.aratana.com/PI. ENT-0064 Until now, there have been limited therapeutic options to restore appetite. That's why we created ENTYCE ® (capromorelin oral solution), the only FDA-approved therapeutic designed to safely and effectively stimulate appetite in dogs. ENTYCE works by mimicking the hunger hormone ghrelin. Administered orally once a day, ENTYCE is appropriate to treat inappetence caused by chronic and acute conditions. Finally, appetite stimulation is in your control Turn on appetite

Articles in this issue

Links on this page

Archives of this issue

view archives of Today's Veterinary Practice - TVP_JUL-AUG2018